Using caffeoyl pyrrolidine derivative LY52, a potential inhibitor of matrix metalloproteinase-2, to suppress tumor invasion and metastasis

International Journal of Molecular Medicine

Volumn 18, Issue 4, 2006, Pages 609-614

  Qu, Xian Jun ^a   Yuan, Yun Xia ^a   Tian, Zhi Gang ^a   Xu, Wen Fang ^a   Chen, Ming Hui ^a   Cui, Shu Xiang ^b   Guo, Qian ^b   Gai, Ruoyan ^c   Makuuchi, Masatoshi ^c   Nakata, Munehiro ^a,d   Tang, Wei ^a,c  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TOKYO   (Japan)

^d TOKAI UNIVERSITY   (Japan)

Author keywords

Caffeoyl pyrrolidine derivative; LY52; Matrix metalloproteinase 2; Metastasis; Tumor invasion

Indexed keywords

CAFFEIC ACID DERIVATIVE; DRUG DERIVATIVE; GELATINASE A; LY52 COMPOUND; PROLINE; PROTEINASE INHIBITOR;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BREAST TUMOR; C57BL MOUSE; CELL MOTION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; EXPERIMENTAL MELANOMA; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; METASTASIS; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CAFFEIC ACIDS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR STRUCTURE; PROLINE; PROTEASE INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34547734676     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.18.4.609     Document Type: Article

References (33)

1. Rundhaug JE: Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9: 267-285, 2005.
2. Wang J, Levenson AS and Satcher RL Jr: Identification of a unique set of genes altered during cell-cell contact in an in vitro model of prostate cancer bone metastasis. Int J Mol Med 17: 849-856, 2006.
3. Gonnella NC, Li YC, Zhang X and Paris CG: Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy. Bioorg Med Chem 5: 2193-2201, 1997. (Pubitemid 28012607)
4. Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SM, Barratt DG, Slater AM, McPheat WL, Waterson D, Henney AM and Pauptit RA: Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol 319: 173-181, 2002.
5. Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M and Yodo M: Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. J Med Chem 42: 1723-1738, 1999.
6. Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A, Tschesche H and Maskos K: Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J 17: 5238-5248, 1998.
7. Rossello A, Nuti E, Orlandini E, Carelli P, Rapposelli S, Macchia M, Minutolo F, Carbonaro L, Albini A, Benelli R, Cercignani G, Murphy G and Balsamo A: New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg Med Chem 12: 2441-2450, 2004.
8. Li YL and Xu WF: Design, synthesis, and activity of caffeoyl pyrrolidine derivatives as potential gelatinase inhibitors. Bioorg Med Chem 12: 5171-5180, 2004.
9. Li X, Li Y and Xu W: Design, synthesis, and evaluation of novel galloyl pyrrolidine derivatives as potential anti-tumor agents. Bioorg Med Chem 14: 1287-1293, 2006. (Pubitemid 43120266)
10. Pulyaeva H, Bueno J, Polette M, Birembaut P, Sato H, Seiki M and Thompson EW: MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin Exp Metastasis 15: 111-120, 1997.
11. Qu XJ, Yang JL, Russell PJ and Goldstein D: Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. J Urol 172: 733-738, 2004.
12. Baragi VM, Shaw BI, Renkiewicz RR, Kuipers PJ, Welgus HG, Mathrubutham M, Cohen JR and Rao SK: A versatile assay for gelatinases using succinylated gelatin. Matrix Biol 19: 267-273, 2000.
13. Yucel T, Mutnal A, Fay K, Fligiel SE, Wang T, Johnson T, Barker SR and Varani J: Matrix metalloproteinase expression in basal cell carcinoma: relationship between enzyme profile and collagen fragmentation pattern. Exp Mol Pathol 79: 151-160, 2005. (Pubitemid 41262497)
14. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF and Tanus-Santos JE: Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 38: 410-414, 2005.
15. Yu M, Sato H, Seiki M, Spiegel S and Thompson EW: Calcium influx inhibits MT1-MMP processing and blocks MMP-2 activation. FEBS Lett 412: 568-572, 1997.
16. Cui SX, Qu XJ, Xie YY, Zhou L, Nakata M, Makuuchi M and Tang W: Curcumin inhibits telomerase activity in human cancer cell lines. Int J Mol Med 18: 227-231, 2006.
17. Tang W, Inagaki Y, Kokudo N, Guo Q, Seyama Y, Nakata M, Imamura H, Sano K, Sugawara Y and Makuuchi M: KL-6 mucin expression in carcinoma of the ampulla of Vater: association with cancer progression. World J Gastroenterol 11: 5450-5454, 2005.
18. Tian B, Li Y, Ji XN, Chen J, Xue Q, Ye SL, Liu YK and Tang ZY: Basement membrane proteins play an active role in the invasive process of human hepatocellular carcinoma cells with high metastasis potential. J Cancer Res Clin Oncol 131: 80-86, 2005.
19. Chang WW, Yu CY, Lin TW, Wang PH and Tsai YC: Soyasaponin I decreases the expression of alpha2, 3-linked sialic acid on the cell surface and suppresses the metastatic potential of B16F10 melanoma cells. Biochem Biophs Res Commun 341: 614-619, 2006.
20. Kontogiorgis CA, Papaioannou P and Hadjipavlou-Litina DJ: Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q) SARs results. Curr Med Chem 12: 339-355, 2005.
21. Mendes O, Kim HT and Stoica G: Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis 22: 237-246, 2005.
22. Onisto M, Slongo ML, Gregnanin L, Gastaldi T, Carli M and Rosolen A: Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 27: 791-798, 2005.
23. Gao ZB, Duan YQ, Zhang L, Chen DW and Ding PT: Expression of matrix metalloproteinase 2 and its tissue inhibitor in oral squamous cell carcinoma. Int J Mol Med 16: 599-603, 2005.
24. Haupt LM, Thompson EW, Trezise AE, Irving RE, Irving MG and Griffiths LR: In vitro and in vivo MMP gene expression localization by In Situ-RT-PCR in cell culture and paraffin embedded human breast cancer cell line xenografts. BMC Cancer 6: 18, 2006.
25. Gilles C, Polette M, Seiki M, Birembaut P and Thompson EW: Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest 76: 651-660, 1997. (Pubitemid 27225095)
26. Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW and Strongin AY: MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 263: 209-223, 2001.
27. Bartsch JE, Staren ED and Appert HE: Matrix metalloproteinase expression in breast cancer. J Surg Res 110: 383-392, 2003.
28. Szabo KA and Singh G: Modulation of monocyte matrix metalloproteinase-2 by breast adenocarcinoma cells. Breast Cancer Res 7: R661-R668, 2005.
29. Philip S, Bulbule A and Kundu GC: Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 276: 44926-44935, 2001.
30. Levitt NC, Eskens F A, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM, Nakajima M, Talbot DC, Steward WP, Harris AL and Verweij J: Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 7: 1912-1922, 2001.
31. Eatock M, Cassidy J, Johnson J, Morrison R, Devlin M, Blackey R, Owen S and Twelves C: A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother Pharmacol 55: 39-46, 2005.
32. Baba M, Itoh K and Tatsu M: Glycine-extended gastrin induces matrix metalloproteinase-1- and -3-mediated invasion of human colon cancer cells through type I collagen gel and Matrigel. Int J Cancer 111: 23-31, 2004.
33. Feng X, Danqing S and Yongsu Z: Discussion of the Inhibition of Angiogenesis and its Mechanism. In: Progress of Antineoplasm-drugs and Chemotherapy. Beijing Science Publ. Corp. p243, 2001.